Monitor for the FDA's formal decision in May 2026, which will determine the regulatory pathway and potential U.S. approval timeline for LYTENAVA™. Absent approval, the company may face delays in U.S. commercialization and revenue generation.
Price Chart
Executive Summary
Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a Complete Response Letter (CRL) for its ONS-5010/ LYTENAVA™ biologics license application. A formal decision from the FDA is expected in May 2026.
Key Facts
- Company held an FDR meeting with the FDA on April 21, 2026, to appeal a CRL issued on December 30, 2025, for ONS-5010/ LYTENAVA™.
- The drug is under development for wet AMD and has already received marketing authorization in the EU and UK.
- The company expects a formal decision from the FDA in May 2026.
- No financial figures or material changes to operations were disclosed.
Financial Impact
No immediate financial impact disclosed; outcome depends on FDA's upcoming decision.
Risk Factors
- FDA may uphold the CRL, delaying or blocking U.S. approval.
- Failure to gain U.S. approval could limit commercial potential and impact company valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-046014 |
| Document: tm2612353d1_ex99-1.htm | 0001104659-26-046014 |
| Document: 0001104659-26-046014-index-headers.html | 0001104659-26-046014 |
| Document: 0001104659-26-046014-index.html | 0001104659-26-046014 |
| Document: 0001104659-26-046014.txt | 0001104659-26-046014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access